Stock MNOV MEDICINOVA, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Other languages MediciNova, Inc.

Equities

MNOV

US58468P2065

Market Closed - Nasdaq
Other stock markets
 21:30:00 01/05/2024 BST 		5-day change 1st Jan Change
1.29 USD 0.00% Intraday chart for MediciNova, Inc. -4.80% -14.00%
03-27 MediciNova, Inc. Receives a Notice of Allowance for a New Patent Covering MN-166 for the Treatment of Macular Injury in Japan CI
03-12 Medicinova Announces New Data and Results of Mn-166 in Chlorine Gas-Induced Acute Lung Injury Presented At the 63Rd Annual Meeting of the Society of Toxicology CI

Other languages

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
MediciNova, Inc. Receives a Notice of Allowance for a New Patent Covering MN-166 for the Treatment of Macular Injury in Japan
Medicinova Announces New Data and Results of Mn-166 in Chlorine Gas-Induced Acute Lung Injury Presented At the 63Rd Annual Meeting of the Society of Toxicology
MediciNova, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
MediciNova Receives a Notice of Grant for a New Patent Covering MN-166 for the Treatment of Macular Injury in China
Top Premarket Gainers
MediciNova, Inc. Announces Abstract Regarding MN-166 in Chlorine Gas-Induced Lung Injury Accepted for Presentation at the 63rd Annual Meeting of the Society of Toxicology
MediciNova, Inc. Receives a Notice of Decision to Grant for a New Patent Covering MN-166 for the Treatment of Progressive MS in Europe
Sector Update: Health Care Stocks Lean Down Premarket Monday
MediciNova, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
MediciNova Secures Patent Notice of Allowance in Canada for Amyotrophic Lateral Sclerosis Combination Treatment
MediciNova, Inc. Receives a Notice of Allowance for a New Patent Covering the Combination of MN-166 and Riluzole for the Treatment of Amyotrophic Lateral Sclerosis in Canada
MediciNova Says it Received $1 Million Clinical Development Milestone Payment Under Deal With Sanofi Subsidiary
Sector Update: Health Care Stocks Gain Premarket Thursday
MediciNova Says Ibudilast Improved Pulmonary Function in Lung Injury Study
MediciNova, Inc. Announces Results of Studies Under BARDA Contract to Develop MN 166 as a Medical Countermeasure Against Chlorine Gas-induced Lung Injury
MediciNova Announces Abstract Regarding MN-166 in Glioblastoma Accepted for Presentation at the Annual Meeting of the Society for Neuro-Oncology
MediciNova Says European Patent Office Issued Notice of Intention to Grant on Macular Injury Therapy Application
MediciNova, Inc. Receives A Notice of Intention to Grant for A New Patent Covering MN-166 for the Treatment of Macular Injury in Europe
Sector Update: Health Care Stocks Steady Premarket Wednesday
Fed Minutes Anticipation Lifts Exchange-Traded Funds, Equity Futures Slightly Premarket Wednesday
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. MNOV Stock
  4. News MediciNova, Inc.
  5. Other languages